Evelyn Friedman lost her daughter, Joanne Leshen, on June 26, 2009 to Leukemia. During the grieving process Evelyn, who is an artist and painter was encouraged by a close family friend, Rabbi Donna Berman of Charter Oak Cultural Center, to put on an art show to display her beautiful oil paintings. Her grandson, Lee Leshen, will be curating his grandmother’s first art show here in Hartford this August. “Art 4 Life” will be a one evening exhibit and silent auction to preserve the memory of his mother, Joanne.

Please join us for “Art 4 Life” on Friday, August 6th from 5:00 pm – 7:00 pm at Charter Oak Cultural Center, Hartford. Tickets are $20 and will include entrance into the event, wine and light refreshments. Framed originals will be available by silent auction as well as additional prize drawings will be held. All proceeds to benefit The Leukemia & Lymphoma Society.

Save The Date!

Friday, August 6, 2010

5:00-7:00 p.m.

Charter Oak Cultural Center

21 Charter Oak Avenue, Hartford, CT 06106

Sponsorship Details - Click the RED "DONATE TO TEAM" button (please disregard donation level titles to the right - the levels below are what are needed with regard to sponsorship of this event)

Platinum Sponsor - $1,000 Eight (8) event tickets ($160 total value) Company name/Logo displayed prominently on wall at gallery’s entrance Company logo included on all posters and invitations Company name included in all event e-mail blasts

Gold Sponsor - $500 Four (4) event tickets ($80 total value) Company logo included on all posters and invitations Company name included in all event e-mail blasts

Silver Sponsor - $250 Two (2) event tickets ($40 value) Company name included in all event e-mail blasts

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health organization dedicated to funding blood cancer research, education, and patient services. LLS offers a wide variety of programs and services in support of its mission: cure for leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families.

Since its inception in 1949, LLS has invested more than $680 million in blood cancer research. LLS-funded research has translated into important advances in understanding and treating blood cancers.

Throughout the years, such innovations in cancer medicine have included the following breakthroughs: a combined regimen of radiation and chemotherapy; stem cell transplantation; and new immunotherapies that target cancer cells, with only minimal effect on surrounding healthy cells.

Overall survival rates for people with blood cancer have doubled in the past 30 years because of more sophisticated remedies. In 1960, only 4% of children diagnosed with leukemia survived. Today, approximately 90% are expected to live if they receive the best treatment available. Despite such remarkable progress, every four minutes a person in the US is diagnosed with blood cancer. Every ten minutes a person dies of a blood cancer. Among children and adolescents, leukemia is the number one cancer killer.